MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-26-1047

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma.

Okamoto Shozo, Nomura Kaori, Shiga Tohru, Sugawara Shigeyasu, Oriuchi Noboru, Ito Hiroshi, Takahashi Kazuhiro, Joho Taiki, Kondo Yuto, Hanada Kazuhiko, Ishizuka Naoki, Kobayakawa Masao

СтатьяПеревод в очереди

Аннотация

PURPOSE: The efficacy of current therapeutic options for pheochromocytomas and paragangliomas, such as 131I-meta-iodobenzylguanidine (131I-MIBG), is limited owing to low complete response rates and a requirement for prolonged radiation isolation. In this regard, alpha-emitting meta-astatobenzylguanidine labeled with astatine-211 (²¹¹At-MABG) has demonstrated encouraging non-clinical results in mice, yet its clinical potential remains unclear. This first-in-human, open-label, single-arm, phase 1 clinical study aimed to evaluate the safety, pharmacokinetics, and recommended dose of 211At-MABG.

PATIENTS AND

METHODS

Ten participants with unresectable or metastatic treatment-refractory pheochromocytomas or paragangliomas and confirmed 123I-MIBG uptake were enrolled between June 2022 and May 2025. Using a 3 + 3 dose-escalation design (0.65, 1.3, and 2.1 MBq/kg), they received a single intravenous dose of 211At-MABG.

RESULTS

No dose-limiting toxicities were observed during the 6-week evaluation period. The cumulative urinary excretion of 211At-MABG reached 65.0% within 72 h, indicating rapid systemic clearance. One, seven, and two patients exhibited a partial response, stable disease, and progressive disease, respectively, during a maximum follow-up period of 12 weeks.

CONCLUSIONS

A single dose of 211At-MABG at 2.1 MBq/kg was well tolerated and demonstrated predictable pharmacokinetics. Preliminary antitumor activity was observed, including one partial response during the 12-week period. These findings establish the clinical feasibility of ²¹¹At-MABG and provide a translational foundation for multi-dose, dose-escalation, and biomarker-stratified trials.

Для цитирования: Okamoto Shozo, Nomura Kaori, Shiga Tohru, Sugawara Shigeyasu, Oriuchi Noboru, Ito Hiroshi, Takahashi Kazuhiro, Joho Taiki, Kondo Yuto, Hanada Kazuhiko, Ishizuka Naoki, Kobayakawa Masao. First-in-human, open-label, single-arm phase 1 study of [211At] meta-astatobenzylguanidine in patients with pheochromocytoma or paraganglioma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. DOI: 10.1158/1078-0432.ccr-26-1047.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.